Lp(a) and ASCVD Risk – Hope of the new therapy

Learning Objectives

Upon completion of this program, attendees should be able to

• Describe the association between higher levels of Lp(a) and increased risk of ASCVD
• Review the current recommendations of using Lp(a) for risk stratification
• Introduce the new anti-sense therapy for lowering Lp(a) and the HORIZON trial